What is Redcliffe Genetics?
Based in Noida, India, and established in 2004, Redcliffe Genetics operates as a specialized provider of genetic sequencing and diagnostic services. The company occupies a critical niche in the healthcare technology sector, leveraging advanced genomic analysis to provide actionable medical insights. By integrating sophisticated sequencing technology with clinical diagnostics, Redcliffe Genetics addresses the growing demand for precision medicine in emerging markets. Its market position is defined by a commitment to high-throughput testing and the democratization of genetic health data, serving as a vital link between complex laboratory research and patient-centric care.
How much funding has Redcliffe Genetics raised?
Redcliffe Genetics has raised a total of $61M across 1 funding round:
Series B
$61M
Series B (2022): $61M with participation from LeapFrog Investments
Key Investors in Redcliffe Genetics
LeapFrog Investments
LeapFrog invests in exceptional businesses in Africa and emerging Asia, partnering with their leaders to achieve leaps of growth, profitability, and impact.
What's next for Redcliffe Genetics?
With the successful closure of this major strategic investment, Redcliffe Genetics is poised to enter a phase of aggressive expansion. The capital will likely be deployed toward scaling its laboratory footprint, investing in next-generation sequencing hardware, and broadening its diagnostic portfolio to include more specialized genetic screening services. As the company matures, the focus will shift toward optimizing supply chain efficiencies and deepening its penetration into the broader Asian healthcare market. This strategic pivot is expected to enhance the firm's competitive moat, allowing it to capitalize on the increasing adoption of personalized medicine and preventative health diagnostics across the region.
See full Redcliffe Genetics company page
